Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065975 | 1.00 | TSHR (0.68) | TSHRMEN1GAAKMT2ACA12 | |
| SCHEMBL5055898 | 1.00 | TSHR (0.68) | TSHRMEN1GAAKMT2ACA12 | |
| SCHEMBL29176960 | 0.87 | TSHR (0.54) | TSHRMEN1GAAKMT2ACA12 | |
| SCHEMBL4676199 | 0.85 | TSHR (0.50) | TSHRMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL17604964 | 0.85 | MAOB (0.61) | TSHRHPGDMAOBMAOASCN9A | |
| SCHEMBL17604966 | 0.85 | MAOB (0.61) | TSHRHPGDMAOBMAOASCN9A | |
| SCHEMBL5066246 | 0.84 | GAA (0.70) | TSHRMEN1GAAKMT2ACA12 | |
| SCHEMBL27693587 | 0.84 | GAA (0.70) | TSHRMEN1GAAKMT2ACA12 | |
| SCHEMBL5060615 | 0.84 | GAA (0.70) | TSHRMEN1GAAKMT2ACA12 | |
| Hydrochloric Acid SCHEMBL5967403 | 0.83 | MAOB (0.60) | TSHRHPGDMAOBMAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050250790-A1 | Novel sulfonic acid derivatives | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1572704-A1 | PHOSPHORUS-CONTAINING PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1438298-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | Pfizer Products Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040127465-A1 | Novel phosphorus-containing derivatives | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| WO-2004055031-A1 | PHOSPHORUS-CONTAINING PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| EP-1430041-A2 | NOVEL SULFONIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040058932-A1 | Novel piperazine derivatives | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| US-6649611-B2 | Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1268455-A2 | PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2001072728-A9 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PROD INC (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020107255-A1 | Novel piperazine derivatives | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2001072728-A2 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058932-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | TSHR 3476/4885MEN1 4741/4885GAA 4620/4885 |
| US-20050250790-A1 | Novel sulfonic acid derivatives | MSR1, MYD88, CXCR2 | TSHR 919/4885MEN1 4669/4885GAA 3021/4885 |
| US-20040127465-A1 | Novel phosphorus-containing derivatives | SLC34A2, SLC34A1, SLC20A1 | TSHR 2274/4885MEN1 2934/4885GAA 1647/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | TSHR 1035/4885MEN1 4737/4885GAA 3225/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | TSHR 2361/4885MEN1 4452/4885GAA 2240/4885 |
| US-20020107255-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | TSHR 3476/4885MEN1 4741/4885GAA 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.